Novartis Presents Two-Year Ianalumab Results in Sjögren’s Disease

John Kim

1 min read

Add as a preferred source on Google

Novartis Presents Two-Year Ianalumab Results in Sjögren’s Disease

Results from the NEPTUNUS extension study showed further improvements in disease activity.

By John Kim

Published Nov 11, 2026, 1:48 PM EST

An unmarked vial rests beside a microscope slide in soft daylight / TokenPost.ai

Novartis presented long-term results from the NEPTUNUS extension study of ianalumab in Sjögren’s disease. The two-year results showed further improvements in disease activity.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.